These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 38340253)

  • 1. Risk of Stroke in Real-World US Individuals with Type 2 Diabetes Receiving Semaglutide or a Dipeptidyl Peptidase 4 Inhibitor.
    Evans M; Husain M; Srivastava A; Mangla KK; Kuhlman AB; Lingvay I
    Adv Ther; 2024 May; 41(5):1843-1859. PubMed ID: 38340253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-World Effectiveness of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists (OW GLP-1RAs) in Comparison with Dipeptidyl Peptidase-4 Inhibitors (DPP-4is) for Glycemic Control and Weight Outcomes in Type 2 Diabetes Mellitus (RELATE).
    Tan X; Divino V; Amamoo J; Xie L; Coyle KB; Gamble CL; Guevarra M; Paprocki Y; King AA
    Clin Drug Investig; 2024 Apr; 44(4):271-284. PubMed ID: 38507188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Once-weekly glucagon-like peptide-1 receptor agonists vs dipeptidyl peptidase-4 inhibitors: cardiovascular effects in people with diabetes and cardiovascular disease.
    Tan X; Liang Y; Rajpura JR; Yedigarova L; Noone J; Xie L; Inzucchi S; de Havenon A
    Cardiovasc Diabetol; 2023 Nov; 22(1):319. PubMed ID: 37985992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Demographic and Clinical Profiles of Type 2 Diabetes Mellitus Patients Initiating Canagliflozin Versus DPP-4 Inhibitors in a Large U.S. Managed Care Population.
    Grabner M; Peng X; Geremakis C; Bae J
    J Manag Care Spec Pharm; 2015 Dec; 21(12):1204-12. PubMed ID: 26679969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes.
    Seino Y; Terauchi Y; Osonoi T; Yabe D; Abe N; Nishida T; Zacho J; Kaneko S
    Diabetes Obes Metab; 2018 Feb; 20(2):378-388. PubMed ID: 28786547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized trial.
    McGuire DK; Busui RP; Deanfield J; Inzucchi SE; Mann JFE; Marx N; Mulvagh SL; Poulter N; Engelmann MDM; Hovingh GK; Ripa MS; Gislum M; Brown-Frandsen K; Buse JB
    Diabetes Obes Metab; 2023 Jul; 25(7):1932-1941. PubMed ID: 36945734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adherence and persistence among patients with type 2 diabetes initiating dulaglutide compared with semaglutide and exenatide BCise: 6-month follow-up from US real-world data.
    Mody R; Yu M; Nepal B; Konig M; Grabner M
    Diabetes Obes Metab; 2021 Jan; 23(1):106-115. PubMed ID: 32945083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Sodium-Glucose Cotransporter-2 Inhibitor and Dipeptidyl Peptidase-4 Inhibitor on the Risks of New-Onset Atrial Fibrillation, Stroke and Mortality in Diabetic Patients: A Propensity Score-Matched Study in Hong Kong.
    Lee S; Zhou J; Leung KSK; Wai AKC; Jeevaratnam K; King E; Liu T; Wong WT; Chang C; Wong ICK; Cheung BMY; Tse G; Zhang Q
    Cardiovasc Drugs Ther; 2023 Jun; 37(3):561-569. PubMed ID: 35142921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sodium-Glucose Cotransporter 2 Inhibitors and Nephrolithiasis Risk in Patients With Type 2 Diabetes.
    Paik JM; Tesfaye H; Curhan GC; Zakoul H; Wexler DJ; Patorno E
    JAMA Intern Med; 2024 Mar; 184(3):265-274. PubMed ID: 38285598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of switching from a dipeptidyl peptidase-4 inhibitor to oral semaglutide on glucose metabolism in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, parallel-group comparison study (the SWITCH-SEMA 2 study).
    Nomoto H; Furusawa S; Nakamura A; Takeuchi J; Nagai S; Yokoyama H; Sakuma I; Taneda S; Kurihara Y; Aoki S; Miya A; Kameda H; Cho KY; Atsumi T; Miyoshi H
    BMJ Open; 2022 May; 12(5):e056885. PubMed ID: 35584872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care.
    Patorno E; Pawar A; Franklin JM; Najafzadeh M; Déruaz-Luyet A; Brodovicz KG; Sambevski S; Bessette LG; Santiago Ortiz AJ; Kulldorff M; Schneeweiss S
    Circulation; 2019 Jun; 139(25):2822-2830. PubMed ID: 30955357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary Occurrence of Cardiovascular Events After Adding Sodium-Glucose Cotransporter-2 Inhibitors or Glucagon-like Peptide-1 Receptor Agonists Compared With Dipeptidyl Peptidase-4 Inhibitors: A Cohort Study in Veterans With Diabetes.
    Richardson TL; Halvorson AE; Hackstadt AJ; Hung AM; Greevy R; Grijalva CG; Elasy TA; Roumie CL
    Ann Intern Med; 2023 Jun; 176(6):751-760. PubMed ID: 37155984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of once-weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: A randomized trial.
    Kaku K; Yamada Y; Watada H; Abiko A; Nishida T; Zacho J; Kiyosue A
    Diabetes Obes Metab; 2018 May; 20(5):1202-1212. PubMed ID: 29322610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing once-weekly semaglutide to incretin-based therapies in patients with type 2 diabetes: a systematic review and meta-analysis.
    Mishriky BM; Cummings DM; Powell JR; Sewell KA; Tanenberg RJ
    Diabetes Metab; 2019 Apr; 45(2):102-109. PubMed ID: 30243806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials.
    Husain M; Bain SC; Holst AG; Mark T; Rasmussen S; Lingvay I
    Cardiovasc Diabetol; 2020 Sep; 19(1):156. PubMed ID: 32998732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Semaglutide on Stroke Subtypes in Type 2 Diabetes: Post Hoc Analysis of the Randomized SUSTAIN 6 and PIONEER 6.
    Strain WD; Frenkel O; James MA; Leiter LA; Rasmussen S; Rothwell PM; Sejersten Ripa M; Truelsen TC; Husain M
    Stroke; 2022 Sep; 53(9):2749-2757. PubMed ID: 35582947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Once-weekly semaglutide use in patients with type 2 diabetes: Results from the SURE France multicentre, prospective, observational study.
    Mohammedi K; Belhatem N; Berentzen TL; Catarig AM; Potier L
    Diabetes Obes Metab; 2023 Jul; 25(7):1855-1864. PubMed ID: 36869853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dipeptidyl peptidase-4 inhibitor compared with sulfonylurea in combination with metformin: cardiovascular and renal outcomes in a propensity-matched cohort study.
    Kim KJ; Choi J; Lee J; Bae JH; An JH; Kim HY; Yoo HJ; Seo JA; Kim NH; Choi KM; Baik SH; Kim SG; Kim NH
    Cardiovasc Diabetol; 2019 Mar; 18(1):28. PubMed ID: 30857540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide.
    Hathaway JT; Shah MP; Hathaway DB; Zekavat SM; Krasniqi D; Gittinger JW; Cestari D; Mallery R; Abbasi B; Bouffard M; Chwalisz BK; Estrela T; Rizzo JF
    JAMA Ophthalmol; 2024 Aug; 142(8):732-739. PubMed ID: 38958939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Study design and baseline profile for adults with type 2 diabetes in the once-weekly subcutaneous SEmaglutide randomized PRAgmatic (SEPRA) trial.
    Buse JB; Nordahl Christensen H; Harty BJ; Mitchell J; Soule BP; Zacherle E; Cziraky M; Willey VJ
    BMJ Open Diabetes Res Care; 2023 May; 11(3):. PubMed ID: 37137527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.